Last reviewed · How we verify
Janus Kinase Inhibitor
Janus Kinase Inhibitors block JAK proteins, which are intracellular signaling enzymes that transmit inflammatory and immune signals from cell surface receptors to the nucleus.
Janus Kinase Inhibitors block JAK proteins, which are intracellular signaling enzymes that transmit inflammatory and immune signals from cell surface receptors to the nucleus. Used for Rheumatoid arthritis, Ulcerative colitis, Atopic dermatitis.
At a glance
| Generic name | Janus Kinase Inhibitor |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Janus Kinase Inhibitor |
| Target | JAK1, JAK2, JAK3, TYK2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
JAK inhibitors prevent the phosphorylation and activation of STAT proteins downstream of cytokine receptors, thereby suppressing inflammatory cytokine signaling pathways. This reduces the proliferation and activation of immune cells, making them useful for treating autoimmune and inflammatory conditions. Different JAK inhibitors have varying selectivity for JAK1, JAK2, JAK3, and TYK2 isoforms, which influences their therapeutic profile and side effects.
Approved indications
- Rheumatoid arthritis
- Ulcerative colitis
- Atopic dermatitis
- Psoriasis
Common side effects
- Infections (upper respiratory, urinary tract)
- Elevated cholesterol
- Headache
- Diarrhea
- Hypertension
- Thrombosis (venous/arterial)
Key clinical trials
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (PHASE1)
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease (PHASE2)
- Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications (PHASE1, PHASE2)
- Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)
- Baricitinib for Reduction of HIV - CNS (PHASE2)
- Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Janus Kinase Inhibitor CI brief — competitive landscape report
- Janus Kinase Inhibitor updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI